These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 10740290)
1. Elucidating cell signaling mechanisms using antisense technology. Koller E; Gaarde WA; Monia BP Trends Pharmacol Sci; 2000 Apr; 21(4):142-8. PubMed ID: 10740290 [TBL] [Abstract][Full Text] [Related]
2. Towards genomic drug therapy with antisense oligonucleotides. Lönnberg H; Vuorio E Ann Med; 1996 Dec; 28(6):511-22. PubMed ID: 9017110 [TBL] [Abstract][Full Text] [Related]
3. Application of antisense oligonucleotides for gene functionalization and target validation. Bennett CF; Cowsert LM Curr Opin Mol Ther; 1999 Jun; 1(3):359-71. PubMed ID: 11713801 [TBL] [Abstract][Full Text] [Related]
4. Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue. Golden T; Dean NM; Honkanen RE Microcirculation; 2002 Jan; 9(1):51-64. PubMed ID: 11896559 [TBL] [Abstract][Full Text] [Related]
5. Nucleic-acid therapeutics: basic principles and recent applications. Opalinska JB; Gewirtz AM Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257 [TBL] [Abstract][Full Text] [Related]
6. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes]. Sommer W; Heilig M Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826 [TBL] [Abstract][Full Text] [Related]
13. Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Altmann KH; Fabbro D; Dean NM; Geiger T; Monia BP; Müller M; Nicklin P Biochem Soc Trans; 1996 Aug; 24(3):630-7. PubMed ID: 8878817 [No Abstract] [Full Text] [Related]
14. Antisense therapeutics: from theory to clinical practice. Pirollo KF; Rait A; Sleer LS; Chang EH Pharmacol Ther; 2003 Jul; 99(1):55-77. PubMed ID: 12804699 [TBL] [Abstract][Full Text] [Related]
15. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Agrawal S Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997 [TBL] [Abstract][Full Text] [Related]
16. Reduction of a vascular endothelial growth factor receptor, fetal liver kinase-1, by antisense oligonucleotides induces motor neuron death in rat spinal cord exposed to hypoxia. Shiote M; Nagano I; Ilieva H; Murakami T; Narai H; Ohta Y; Nagata T; Shoji M; Abe K Neuroscience; 2005; 132(1):175-82. PubMed ID: 15780476 [TBL] [Abstract][Full Text] [Related]
17. Pharmacology of antisense oligonucleotide inhibitors of protein expression. Cooper SR; Taylor JK; Miraglia LJ; Dean NM Pharmacol Ther; 1999; 82(2-3):427-35. PubMed ID: 10454217 [TBL] [Abstract][Full Text] [Related]
19. The therapeutic potential of antisense oligonucleotides. Sharma HW; Narayanan R Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067 [TBL] [Abstract][Full Text] [Related]
20. GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation. Sternberger M; Schmiedeknecht A; Kretschmer A; Gebhardt F; Leenders F; Czauderna F; Von Carlowitz I; Engle M; Giese K; Beigelman L; Klippel A Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):131-43. PubMed ID: 12162696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]